Afficher la notice abrégée

Étude médicoéconomique comparant l’impact du traitement par aprotinine versus acide tranexamique en chirurgie cardiaque sous circulation extracorporelle

dc.rights.licenseopenen_US
dc.contributor.authorHUYNH, Clémence
dc.contributor.authorCRUBEZY, Isabelle
dc.contributor.authorTRIN, Kilian
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPERINO, Justine
ORCID: 0000-0003-0039-0734
IDREF: 254309690
dc.contributor.authorONG, Nathalie
dc.contributor.authorRAMAROSON, Hanta
dc.contributor.authorPUNTOUS, Maryse
dc.contributor.authorGALLO, Eloise
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorOUATTARA, Alexandre
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorXUEREB, Fabien
dc.date.accessioned2024-09-25T08:58:05Z
dc.date.available2024-09-25T08:58:05Z
dc.date.issued2024-07-29
dc.identifier.issn0003-4509en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201794
dc.description.abstractEnAn increased risk of mortality and postoperative side effects led to aprotinin (Trasylol®) withdrawal from the market in 2008, but since 2018 aprotinin has again been used in France. The French retrospective multicentre APACHE study (AProtinin versus tranexamic Acid in Cardiac surgery patients with High-risk for Excessive bleeding) compared the efficacy of tranexamic acid versus half-dose aprotinin. The aim of this study, ancillary to the APACHE study, is to carry out a medico-economic analysis of the use of these two antifibrinolytics on an APACHE subpopulation. Economic data on reimbursement by the French health insurance system were extracted from the program for the data processing of medical information, and quantitative data on the cost of healthcare products were obtained from the hospital pharmacy software. The main analysis of costs for the population shows that the global valuation was not significantly different between the two treatment groups (P=0.60), but the costs of blood products included in the related hospital stay group (Groupe Homogène de séjour [GHS]) (whole blood, platelets and plasma) were higher for the tranexamic acid group (P=0.007). In a sub-analysis of patients alive at discharge, the costs of blood products in addition to GHS (blood-derived medicines) and the costs of blood products in the GHS were higher for the tranexamic acid group (P=0.04 and 0.001, respectively). The additional cost of aprotinin at the time of purchase is offset by the additional costs of blood products in the tranexamic acid group.
dc.language.isoFRen_US
dc.subjectAcide tranexamique
dc.subjectAprotinine
dc.subjectCirculation extracorporelle
dc.subjectÉtude médicoéconomique
dc.subject.enAprotinin
dc.subject.enCardiopulmonary bypass
dc.subject.enCost analysis study
dc.subject.enTranexamic acid
dc.titleÉtude médicoéconomique comparant l’impact du traitement par aprotinine versus acide tranexamique en chirurgie cardiaque sous circulation extracorporelle
dc.title.enCost analysis study comparing the impact of treatment with aprotinin versus tranexamic acid in cardiac surgery under cardiopulmonary bypass.
dc.title.alternativeAnn Pharm Fren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.pharma.2024.07.005en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39084283en_US
bordeaux.journalAnnales Pharmaceutiques Françaisesen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04708881
hal.version1
hal.date.transferred2024-09-25T08:58:08Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.title=%C3%89tude%20m%C3%A9dico%C3%A9conomique%20comparant%20l%E2%80%99impact%20du%20traitement%20par%20aprotinine%20versus%20acide%20tranexamique%20en%20chirurgie%20cardiaque%2&rft.atitle=%C3%89tude%20m%C3%A9dico%C3%A9conomique%20comparant%20l%E2%80%99impact%20du%20traitement%20par%20aprotinine%20versus%20acide%20tranexamique%20en%20chirurgie%20cardiaque%&rft.jtitle=Annales%20Pharmaceutiques%20Fran%C3%A7aises&rft.date=2024-07-29&rft.eissn=0003-4509&rft.issn=0003-4509&rft.au=HUYNH,%20Cl%C3%A9mence&CRUBEZY,%20Isabelle&TRIN,%20Kilian&PERINO,%20Justine&ONG,%20Nathalie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée